Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoVaccine Technologies, a vaccine development company, has received patent approval from the Japanese Patent Office for its vaccine platform.
Subscribe to our email newsletter
The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.
Securing broad patent coverage is said to be part of ImmunoVaccine Technologies’s (IVT) strategy to maximize the market potential of its VacciMax platform in the pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan.
The company’s VacciMax technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination.
Randal Chase, president and CEO of IVT, said: “The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology. We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products.”